Keros Therapeutics, Inc. presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on September 6, 2025. The data further highlighted the broad therapeutic potential of KER-065.
The results demonstrated robust bone anabolic activity, including statistically significant increases in bone mineral density (BMD) at the lumbar spine and total hip. Additionally, treatment with KER-065 led to increases in bone formation markers and decreases in bone resorption markers, indicating a positive impact on bone health.
Treatment with KER-065 was generally well-tolerated across all dose levels tested, with no dose-limiting toxicities or serious adverse events reported. These findings continue to support the development of KER-065 for Duchenne muscular dystrophy, where bone loss is a significant concern due to progressive muscle weakness and chronic corticosteroid use.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.